March 12, 2024
Genmab said on March 11 that it has filed its IgG1 bispecific antibody Epkinly (epcoritamab), being codeveloped with AbbVie, for an additional indication of relapsed or refractory follicular lymphoma (Grade 1-3A) in Japan. In Japan, Epkinly was approved in September...read more